Results

Total Results: 2,231 records

Showing results for "disease".

341. Renal-Function Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/renal-function_executive.pdf
     August 01, 2014 - ; CHD = coronary heart disease; CKD = chronic kidney disease; ESRD = end-stage renal disease; KQ = Key … National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic … Diseases. … Plasma elimination of cardiac troponin I in end-stage renal disease. … Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American

342. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/13_pulmonary_potential_high_impact_2012-12-11.pdf
     January 01, 2012 - Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 13: Pulmonary Disease … Healthcare Horizon Scanning System Potential High- Impact Interventions: Priority Area 13: Pulmonary Disease … ES-2 Pulmonary Disease, Including Asthma, Interventions ........................................... … Priority Area 13: Pulmonary Disease, Including Asthma Topic High-Impact Potential 1. * Ivacaftor … The experts deemed one topic as having potential for high impact—a new disease-modifying drug targeted

343. PHARMACO-EPIDEMIOLOGIC METHODS FOR A STUDY OF (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotic-medicine-mortality-elderly_research.pdf
     March 01, 2009 - Initiators of conventional APMs also had a higher risk for death due to respiratory diseases, nervous … system diseases and other causes. … disease. … , respiratory diseases, nervous system and other causes (Table 3). … International classification of diseases 9th revision clinical modification.

344. Research White Paper Biorepositories Addendum Registries For Evaluating Patient Outcomes Third Edition (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/biorepositories-registries-guide-3rd-ed-addendum-white-paper.pdf
     February 01, 2018 - biospecimens, and this knowledge is being used to conduct further research to better understand how diseases … , the biology of the disease. … data can enable longitudinal research studies to examine the biological and genetic risk factors for diseases … The majority of biorepositories focus on collecting material from patients diagnosed with specific diseases … , and treatment of a wide range of serious and life-threatening illnesses, including cancer, heart diseases

345. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0404_01-14-2011.pdf
     January 01, 2011 - )  PAH is a progressive and incurable disease with a variety of etiologies and a pathology that … Based on disease etiology and severity of the disease, the timing and optimal combinations of drug therapy

346. Methods Guide for Medical Test Reviews (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-bias_methods.pdf
     July 01, 2012 - standard, defined as the best comparator test to diagnose the disease or health condition in question … Interpreters may consider test results to be positive more frequently in settings with higher disease … Disease progression bias Occurs when the index test is performed an unusually long time before the … report is the true disease status); in this case, the disease status is verified in the AFFECTED relatives … Systematic review: family history in risk assessment for common diseases.

347. Disposition of Comments for CER 211: Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-211-rheumatoid-arthritis-disposition-comments.pdf
     December 20, 2018 - activity” – not exactly improved disease activity, improved disease control? … discovering, developing, and delivering innovative, transformational medicines for patients with serious diseases … Since we know that autoimmune diseases evolve as a continuum starting years before the first clinical … is treatment- naïve disease. … Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration.

348. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1506.pdf
     June 01, 2015 - Potential High-Impact Interventions Report Priority Area 04: Dementia (Including Alzheimer’s Disease … Scanning System Potential High- Impact Interventions: Priority Area 04: Dementia (Including Alzheimer’s Disease … Priority Area 04: Dementia (Including Alzheimer’s Disease) Topic High-Impact Potential 1. … Off-label intranasal insulin for treatment of Alzheimer’s disease No high-impact potential; archived … that treatments that safely increase insulin levels or insulin signaling efficiency might improve disease

349. Santa_ECCS2012 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/santa_eccs2012.pdf
     February 01, 2013 - Slide 7: Comparison of Heart Disease Screening  Tests  (1 of 2) • Began  with the grades used … Preventive Services Task  Force. • Built ratings of common coronary or vascular disease screening … tests. • Added new evidence, frequency/burden  of disease, cost, and application to other  diseases … rated  tests  underused   o Poorly  rated  tests  overused Slide 8: Comparison of Heart Disease … • These people significantly overestimated their risk for cardiovascular disease.

350. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - in this field focuses on drugs and biologics for irritable bowel syndrome and inflammatory bowel diseases … , biliary tract disease, and pancreatic disease. … National Digestive Diseases Information Clearinghouse (NDDIC). Short bowel syndrome. … Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National … Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including

351. Colorectal-Cancer-Protocol_130520 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/colorectal-cancer-staging_research-protocol.pdf
     May 20, 2013 - For stage I, II, and III disease, surgical resection is the primary treatment. … Approximately 20% to 30% of patients develop recurrent disease. … Disease characteristics (e.g., tumor grade) iii. … Disease characteristics (e.g., tumor grade) iii. … colorectal cancer” as an inclusion criterion, colon cancer and rectal cancer are somewhat different diseases

352. Disposition of Comments Report for Local Therapies for Unresectable Primary Hepatocellular Carcinoma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer-therapy_disposition-comments.pdf
     May 24, 2013 - This is because patients with different disease characteristics are candidates for different treatments … patients with small accessible tumors are candidates for ablation whereas more extensive disease would … If they have more advanced disease (intermediate-staged HCC) with multifocal tumors or large tumors … Ablative therapies are limited to patients with very to early stage disease and are never used for … TEA(TAE) are both patients with multifocal disease.

353. Treatment of Stage I-III Squamous Cell Anal Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/anal-cancer-protocol.pdf
     September 26, 2023 - Diseases of the Colon & Rectum. 2018;61(7):755-74. 5. Bojko MM, Kucejko RJ, Poggio JL. … Anal squamous cell carcinoma: an evolution in disease and management. … Mitomycin induced pulmonary veno- occlusive disease. … management/ or exp disease progression/ or disease resistance/ or Endoscopy/ or Magnetic Resonance … management or monitor* or disease progress* or disease resistan* or magnetic resonance imaging or

354. S66 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s66.pdf
     October 01, 2007 - ORIGINAL ARTICLE Assessment of Adherence to and Persistence on Disease-Modifying Antirheumatic Drugs … Griffin, MD, MPH*§¶ Objective: Biologic disease-modifying antirheumatic drugs (DMARDs) are efficacious … Key Words: rheumatoid arthritis, disease-modifying antirheumatic drugs (Med Care 2007;45: S66–S76) … Clinical trials have shown that these medications improve symptoms and retard disease progression.7–11 … transplantation, HIV/AIDS, cancer (except nonmelanoma skin cancers), and serious renal, liver, or respiratory diseases

355. Disposition of Comments Report for Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal Complaints in Children (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/musculoskeletal-complaints-tests-children_disposition-comments.pdf
     March 07, 2012 - No child can be said to have (or not have) any disease (SLE, JIA or any other disease) with only the … providers (who have widely varying ability and experience in the field of pediatric musculoskeletal diseases … report by an ACR Ad Hoc committee the performance of these assays for the diagnosis of autoimmune diseases … The health care provider orders these tests, trying to distinguish autoimmune diseases from other causes … Reviewer #4 I do think that as far as these tests being used for confirmation of the specific diseases

356. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/vaccine-safety_research-protocol.pdf
     September 18, 2012 - their role in eradicating smallpox and controlling polio, measles, rubella, and other infectious diseases … pregnant women.5 Increasing vaccination rates remains critically important, as vaccine-preventable diseases … Centers for Disease Control and Prevention. … Centers for Disease Control and Prevention. … Centers for Disease Control and Prevention.

357. S16 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s16.pdf
     October 01, 2007 - Research using cohort and case-control designs, disease and intervention registries, and outcomes studies … Adherence to therapies Disease stage and severity Risk of complications or side-effects of therapy … Trials; registries25 Adherence high in RCTs and community patients with heart disease (�80%); little … CEA indicates carotid endarterectomy; CVD, cardiovascular disease. … A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

358. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cognitive-decline_executive.pdf
     March 01, 2017 - will be seen as more salient. 3 Interventions have been developed to prevent or treat chronic diseases … Common diseases that cause cognitive decline, especially CATD, progress slowly. … does not include dementia due to specific, identifiable conditions such as Lewy body, infectious diseases … Preventing Alzheimer’s disease and cognitive decline. … Advances in the prevention of Alzheimer’s disease and dementia.

359. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cognitive-decline_executive.pdf
     March 01, 2017 - will be seen as more salient. 3 Interventions have been developed to prevent or treat chronic diseases … Common diseases that cause cognitive decline, especially CATD, progress slowly. … does not include dementia due to specific, identifiable conditions such as Lewy body, infectious diseases … Preventing Alzheimer’s disease and cognitive decline. … Advances in the prevention of Alzheimer’s disease and dementia.

360. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/musculoskeletal-complaints-tests-children_research-protocol.pdf
     September 29, 2010 - However, MSK pain is neither a necessary nor sufficient indicator of rheumatic diseases (for instance … Diagnoses of both rheumatic and non-rheumatic diseases are made only after an appropriate patient history … Disease Registry. … / or arm/ or leg/ or extremities/ 80 exp Rheumatic Diseases/di, co, et, im, pa, pp 21 132 and 136 … 81 exp Connective Tissue Diseases/di, co, et, im, pa, pp 22 Fibromyalgia/ 82 exp arthritis/di, co,